Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Kisspeptin-10 | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.
Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →